Found 626 clinical trials
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)
This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS
- 0 views
- 06 Aug, 2021
- 43 locations
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)
This clinical study aims to investigate if impairment of the deoxyribonucleic acid damage repair (DDR) pathway by the Elimusertib in combination with blockade of the PD-1/PD-L1 pathway by
- 1 views
- 14 Sep, 2021
- 10 locations
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …
- 229 views
- 26 Aug, 2021
- 199 locations
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer
- 314 views
- 25 Mar, 2021
- 4 locations
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy
- 160 views
- 08 Nov, 2020
- 1 location
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel
- 144 views
- 25 Mar, 2021
- 1 location
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (516-003)
that belongs to a class of drugs known as checkpoint inhibitors; specifically, nivolumab is an inhibitor of the Programmed Cell Death (or PD 1). Cancers can have extra signal molecules (PD-L1
- 80 views
- 02 Jun, 2021
- 36 locations
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
- 356 views
- 08 Nov, 2020
- 2 locations
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other hand, the duration of treatment by
- 22 views
- 25 Jan, 2021
- 46 locations
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na ve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYMAKER-U01B)
that is PD-L1 positive. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
- 0 views
- 05 Sep, 2021
- 27 locations